查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1460612

流行病學人工智慧（AI）全球市場預測（2024-2032）

Global Artificial Intelligence (AI) in Epidemiology Market Forecast 2024-2032
出版日期: | 出版商: Inkwood Research | 英文 299 Pages | 商品交期: 2-3個工作天內

價格

主要發現

預計 2024 年至 2032 年預測期內，全球流行病學人工智慧 (AI) 市場規模的複合年增長率將達到 27.33%。 主要市場成長驅動因素包括對疾病爆發的早期檢測和監測、預測疾病趨勢的預測模型以及流行病學研究數據的可用性的日益增長的需求。

市場洞察

疾病爆發的早期發現和監測對於推動全球流行病學人工智慧 (AI) 市場的成長髮揮著至關重要的作用。 利用人工智慧驅動的演算法處理大量資料集，公共衛生官員可以快速識別新出現的威脅，並及時進行幹預，以減輕傳染病的傳播。 這種積極主動的方法不僅可以挽救生命，還可以降低與治療大規模疫情相關的醫療費用。

此外，人工智慧在流行病學領域的引入將提高疾病監測系統的效率和準確性，使得即時監測人群健康趨勢成為可能。 這種能力使醫療保健利益相關者能夠預測潛在的疫情、有效地分配資源並實施有針對性的干預措施，以盡量減少流行病對公共衛生和經濟的影響。

人工智慧技術日益融入流行病學研究和公共衛生基礎設施，將促進政府、研究機構和產業利益相關者之間的合作。 這些合作夥伴關係將促進人工智慧演算法和數據分析的創新，從而開發出更複雜的疾病檢測、預測和應對工具。 因此，隨著利害關係人認識到早期檢測和監測在保護公眾健康方面的關鍵作用，流行病學領域對人工智慧解決方案的需求持續飆升，推動了全球市場的成長。

區域見解

全球流行病學人工智慧 (AI) 市場成長研究彙編了歐洲、亞太地區、北美和世界其他地區的地理研究。 預計在預測期內，北美將成為全球市場的主導地區。

北美擁有先進的醫療保健基礎設施，配備電子健康記錄 (EHR) 等先進工具和強大的數據系統，可實現人工智慧解決方案的無縫整合和利用。 政府問責辦公室 (GAO) 和美國國家醫學院 (NAM) 正在合作開展一項計劃，檢查人工智慧/機器學習在醫療保健領域的應用，評估其影響，並確定優化其使用的關鍵策略。 這項措施正在顯著加速人工智慧在北美流行病學市場的進展。

競爭考量

在流行病學人工智慧的競爭格局中，各公司競相利用先進的演算法和數據分析來提供創新的解決方案，以增強疾病監測和預測。 領先的公司專注於開發強大的人工智慧模型，這些模型可以有效地分析大量醫療數據，並為公共衛生機構和醫療保健提供者提供可行的見解。

此外，與研究和政府機構的合作對於在這個快速發展的市場中獲得優勢至關重要。 此外，全球市場的頂尖公司還包括Epic Systems Corporation、Microsoft Corporation、Meditech等。

目錄

第一章研究範圍與研究方法

第 2 章執行摘要

  • 市場規模/估計
  • 市場概覽
  • 調查範圍
  • 危機情境分析
  • 主要市場研究結果

第三章市場動態

  • 主要驅動因素
    • 及早發現及監測疾病爆發
    • 用於預測疾病趨勢的預測模型
    • 流行病學研究的數據可用性
  • 主要限制因素
    • 有關敏感患者資料的隱私和道德問題
    • 資料品質和可用性方面的課題

第四章主要分析

  • 主要市場趨勢
    • 機器學習與資料分析的進展
    • 擴展遠距醫療和遠端監控
    • 將人工智慧融入公共衛生系統
  • 波特五力分析
  • 成長前景圖
  • 市場成熟度分析
  • 市場集中度分析

第 5 章市場：依發展劃分

  • 本地
    • 市場預測圖表
    • 細分分析
  • 基於網路
    • 市場預測圖
    • 細分分析
  • 基於雲端
    • 市場預測圖
    • 細分分析

第 6 章市場：依應用劃分

  • 感染預測
    • 市場預測圖
    • 細分分析
  • 疾病/症狀監測
    • 市場預測圖
    • 細分分析
  • 人口健康與發病率/盛行率監測
    • 市場預測圖
    • 細分分析

第 7 章市場：依最終用途劃分

  • 政府/國家機構
    • 市場預測圖
    • 細分分析
  • 實驗室
    • 市場預測圖
    • 細分分析
  • 製藥和生技公司
    • 市場預測圖表
    • 細分分析
  • 醫療保健提供者
    • 市場預測圖表
    • 細分分析

第 8 章區域分析

  • 北美
    • 市場規模/估計
    • 市場驅動因素
    • 市場課題
    • 市場主要參與者
    • 國家分析
  • 歐洲
    • 市場規模/估計
    • 市場驅動因素
    • 市場課題
    • 市場主要參與者
    • 國家分析
  • 亞太地區
    • 市場規模/估計
    • 市場驅動因素
    • 市場課題
    • 市場主要參與者
    • 國家分析
  • 世界其他地區
    • 市場規模/估計
    • 市場驅動因素
    • 市場課題
    • 市場主要參與者
    • 區域分析

第九章競爭態勢

  • 主要策略發展
    • 併購
    • 產品發佈/開發
    • 合作/協議
    • 業務擴張/縮減
  • 公司簡介
    • ALPHABET INC
    • BAYER HEALTHCARE
    • CARDIOLYSE
    • CERNER CORPORATION
    • COGNIZANT
    • ECLINICAL WORKS INC
    • EPIC SYSTEMS CORPORATION
    • INTEL CORPORATION
    • KOMODO HEALTH
    • MEDITECH
    • MICROSOFT CORPORATION
    • PREDIXION HEALTHCARE（JVION LLC）
    • SAS INSTITUTE
    • SIEMENS HEALTHINEERS
Product Code: 82541

KEY FINDINGS

The global artificial intelligence (AI) in epidemiology market is forecasted to generate a CAGR of 27.33% over the projection years of 2024-2032. Key drivers facilitating the market's growth include the early detection and surveillance of disease outbreaks, the growing need for predictive modeling to forecast disease trends, and data availability for epidemiological research.

MARKET INSIGHTS

Early detection and surveillance of disease outbreaks play a pivotal role in driving the growth of the global artificial intelligence (AI) in epidemiology market. By leveraging AI-powered algorithms on vast datasets, public health authorities can swiftly identify emerging threats, enabling timely interventions to mitigate the spread of infectious diseases. This proactive approach not only saves lives but also reduces healthcare costs associated with treating widespread outbreaks.

Furthermore, the adoption of AI in epidemiology enhances the efficiency and accuracy of disease surveillance systems, enabling real-time monitoring of population health trends. This capability enables healthcare stakeholders to anticipate potential outbreaks, allocate resources effectively, and implement targeted interventions, thereby minimizing the impact of epidemics on public health and economies.

The increasing integration of AI technologies into epidemiological research and public health infrastructure fosters collaborations between governments, research institutions, and industry players. These partnerships drive innovation in AI algorithms and data analytics, leading to the development of more sophisticated tools for disease detection, prediction, and response. Consequently, the demand for AI solutions in epidemiology continues to surge, fueling the growth of the global market as stakeholders recognize the critical role of early detection and surveillance in safeguarding public health.

REGIONAL INSIGHTS

The global artificial intelligence (AI) in epidemiology market growth examination compiles the geographical study of Europe, Asia-Pacific, North America, and Rest of World. North America is set to be a major region in the global market during the forecast period.

North America boasts a sophisticated healthcare infrastructure with advanced tools like electronic health records (EHRs) and strong data systems, enabling seamless integration and use of AI solutions. The Government Accountability Office (GAO) and the National Academy of Medicine (NAM) are collaborating on an initiative to explore AI/ML applications in healthcare, assessing their impact and identifying key strategies for optimizing their use. This effort significantly accelerates progress in the North America AI in epidemiology market.

COMPETITIVE INSIGHTS

In the competitive landscape of AI in epidemiology, companies are vying to offer innovative solutions leveraging advanced algorithms and data analytics to enhance disease surveillance and prediction. Key players are focused on developing robust AI models that can efficiently analyze vast amounts of healthcare data to provide actionable insights for public health agencies and healthcare providers.

Additionally, partnerships with research institutions and government bodies are crucial for staying ahead in this rapidly evolving market. Additionally, some of the top companies in the global market are Epic Systems Corporation, Microsoft Corporation, Meditech, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. METHODOLOGY
  • 1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW
  • 2.3. SCOPE OF STUDY
  • 2.4. CRISIS SCENARIO ANALYSIS
    • 2.4.1. IMPACT OF COVID-19 ON ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • 2.5. MAJOR MARKET FINDINGS
    • 2.5.1. PUBLIC-PRIVATE PARTNERSHIP IN AI FOR HEALTH INFECTION PREDICTION & FORECASTING
    • 2.5.2. RISING APPLICATIONS OF AI IN PERSONALIZED MEDICATIONS
    • 2.5.3. INCREASING POPULARITY IN INFECTION PREDICTION AND FORECASTING ON CLOUD-BASED PLATFORMS

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. EARLY DETECTION AND SURVEILLANCE OF DISEASE OUTBREAKS
    • 3.1.2. PREDICTIVE MODELING TO FORECAST DISEASE TRENDS
    • 3.1.3. DATA AVAILABILITY FOR EPIDEMIOLOGICAL RESEARCH
  • 3.2. KEY RESTRAINTS
    • 3.2.1. PRIVACY AND ETHICAL CONCERNS REGARDING SENSITIVE PATIENT DATA
    • 3.2.2. DATA QUALITY AND AVAILABILITY CHALLENGES

4. KEY ANALYTICS

  • 4.1. KEY MARKET TRENDS
    • 4.1.1. ADVANCEMENTS IN MACHINE LEARNING AND DATA ANALYTICS
    • 4.1.2. EXPANSION OF TELEHEALTH AND REMOTE MONITORING
    • 4.1.3. INTEGRATION OF AI IN PUBLIC HEALTH SYSTEMS
  • 4.2. PORTER'S FIVE FORCES ANALYSIS
    • 4.2.1. BUYERS POWER
    • 4.2.2. SUPPLIERS POWER
    • 4.2.3. SUBSTITUTES
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. GROWTH PROSPECT MAPPING
  • 4.4. MARKET MATURITY ANALYSIS
  • 4.5. MARKET CONCENTRATION ANALYSIS

5. MARKET BY DEPLOYMENT

  • 5.1. ON-PREMISE
    • 5.1.1. MARKET FORECAST FIGURE
    • 5.1.2. SEGMENT ANALYSIS
  • 5.2. WEB-BASED
    • 5.2.1. MARKET FORECAST FIGURE
    • 5.2.2. SEGMENT ANALYSIS
  • 5.3. CLOUD-BASED
    • 5.3.1. MARKET FORECAST FIGURE
    • 5.3.2. SEGMENT ANALYSIS

6. MARKET BY APPLICATION

  • 6.1. INFECTION PREDICTION & FORECASTING
    • 6.1.1. MARKET FORECAST FIGURE
    • 6.1.2. SEGMENT ANALYSIS
  • 6.2. DISEASE & SYNDROMIC SURVEILLANCE
    • 6.2.1. MARKET FORECAST FIGURE
    • 6.2.2. SEGMENT ANALYSIS
  • 6.3. MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE
    • 6.3.1. MARKET FORECAST FIGURE
    • 6.3.2. SEGMENT ANALYSIS

7. MARKET BY END USE

  • 7.1. GOVERNMENT & STATE AGENCIES
    • 7.1.1. MARKET FORECAST FIGURE
    • 7.1.2. SEGMENT ANALYSIS
  • 7.2. RESEARCH LABS
    • 7.2.1. MARKET FORECAST FIGURE
    • 7.2.2. SEGMENT ANALYSIS
  • 7.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 7.3.1. MARKET FORECAST FIGURE
    • 7.3.2. SEGMENT ANALYSIS
  • 7.4. HEALTHCARE PROVIDERS
    • 7.4.1. MARKET FORECAST FIGURE
    • 7.4.2. SEGMENT ANALYSIS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.1.3. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.1.4. KEY PLAYERS IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.1.1. UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.1.5.2. CANADA
      • 8.1.5.2.1. CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.2.3. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.2.4. KEY PLAYERS IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. UNITED KINGDOM
      • 8.2.5.1.1. UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.2. GERMANY
      • 8.2.5.2.1. GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.3. FRANCE
      • 8.2.5.3.1. FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.4. ITALY
      • 8.2.5.4.1. ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.5. SPAIN
      • 8.2.5.5.1. SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.2.5.6. REST OF EUROPE
      • 8.2.5.6.1. REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.3. ASIA-PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.3.3. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.3.4. KEY PLAYERS IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.1.1. CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.2. JAPAN
      • 8.3.5.2.1. JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.3. INDIA
      • 8.3.5.3.1. INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.4. SOUTH KOREA
      • 8.3.5.4.1. SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.5. AUSTRALIA & NEW ZEALAND
      • 8.3.5.5.1. AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.3.5.6. REST OF ASIA-PACIFIC
      • 8.3.5.6.1. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
    • 8.4.3. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
    • 8.4.4. KEY PLAYERS IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.1.1. LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
      • 8.4.5.2. MIDDLE EAST & AFRICA
      • 8.4.5.2.1. MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGERS & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 9.1.3. PARTNERSHIPS & AGREEMENTS
    • 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
  • 9.2. COMPANY PROFILES
    • 9.2.1. ALPHABET INC
      • 9.2.1.1. COMPANY OVERVIEW
      • 9.2.1.2. PRODUCT LIST
      • 9.2.1.3. STRENGTHS & CHALLENGES
    • 9.2.2. BAYER HEALTHCARE
      • 9.2.2.1. COMPANY OVERVIEW
      • 9.2.2.2. PRODUCT LIST
      • 9.2.2.3. STRENGTHS & CHALLENGES
    • 9.2.3. CARDIOLYSE
      • 9.2.3.1. COMPANY OVERVIEW
      • 9.2.3.2. PRODUCT LIST
      • 9.2.3.3. STRENGTHS & CHALLENGES
    • 9.2.4. CERNER CORPORATION
      • 9.2.4.1. COMPANY OVERVIEW
      • 9.2.4.2. PRODUCT LIST
      • 9.2.4.3. STRENGTHS & CHALLENGES
    • 9.2.5. COGNIZANT
      • 9.2.5.1. COMPANY OVERVIEW
      • 9.2.5.2. PRODUCT LIST
      • 9.2.5.3. STRENGTHS & CHALLENGES
    • 9.2.6. ECLINICAL WORKS INC
      • 9.2.6.1. COMPANY OVERVIEW
      • 9.2.6.2. PRODUCT LIST
      • 9.2.6.3. STRENGTHS & CHALLENGES
    • 9.2.7. EPIC SYSTEMS CORPORATION
      • 9.2.7.1. COMPANY OVERVIEW
      • 9.2.7.2. PRODUCT LIST
      • 9.2.7.3. STRENGTHS & CHALLENGES
    • 9.2.8. INTEL CORPORATION
      • 9.2.8.1. COMPANY OVERVIEW
      • 9.2.8.2. PRODUCT LIST
      • 9.2.8.3. STRENGTHS & CHALLENGES
    • 9.2.9. KOMODO HEALTH
      • 9.2.9.1. COMPANY OVERVIEW
      • 9.2.9.2. PRODUCT LIST
      • 9.2.9.3. STRENGTHS & CHALLENGES
    • 9.2.10. MEDITECH
      • 9.2.10.1. COMPANY OVERVIEW
      • 9.2.10.2. PRODUCT LIST
      • 9.2.10.3. STRENGTHS & CHALLENGES
    • 9.2.11. MICROSOFT CORPORATION
      • 9.2.11.1. COMPANY OVERVIEW
      • 9.2.11.2. PRODUCT LIST
      • 9.2.11.3. STRENGTHS & CHALLENGES
    • 9.2.12. PREDIXION HEALTHCARE (JVION LLC)
      • 9.2.12.1. COMPANY OVERVIEW
      • 9.2.12.2. PRODUCT LIST
      • 9.2.12.3. STRENGTHS & CHALLENGES
    • 9.2.13. SAS INSTITUTE
      • 9.2.13.1. COMPANY OVERVIEW
      • 9.2.13.2. PRODUCT LIST
      • 9.2.13.3. STRENGTHS & CHALLENGES
    • 9.2.14. SIEMENS HEALTHINEERS
      • 9.2.14.1. COMPANY OVERVIEW
      • 9.2.14.2. PRODUCT LIST
      • 9.2.14.3. STRENGTHS & CHALLENGES

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY
  • TABLE 2: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DEPLOYMENT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 3: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DEPLOYMENT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 4: GLOBAL ON-PREMISE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 5: GLOBAL ON-PREMISE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 6: GLOBAL WEB-BASED MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 7: GLOBAL WEB-BASED MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 8: GLOBAL CLOUD-BASED MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 9: GLOBAL CLOUD-BASED MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 10: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 11: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 12: GLOBAL INFECTION PREDICTION & FORECASTING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 13: GLOBAL INFECTION PREDICTION & FORECASTING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 14: GLOBAL DISEASE & SYNDROMIC SURVEILLANCE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 15: GLOBAL DISEASE & SYNDROMIC SURVEILLANCE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 16: GLOBAL MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 17: GLOBAL MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 18: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY END USE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 19: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY END USE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 20: GLOBAL GOVERNMENT & STATE AGENCIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 21: GLOBAL GOVERNMENT & STATE AGENCIES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 22: GLOBAL RESEARCH LABS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 23: GLOBAL RESEARCH LABS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 24: GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 25: GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 26: GLOBAL HEALTHCARE PROVIDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 27: GLOBAL HEALTHCARE PROVIDERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 28: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 29: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 30: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 31: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 32: KEY PLAYERS OPERATING IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 33: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 34: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 35: KEY PLAYERS OPERATING IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 36: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 37: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 38: KEY PLAYERS OPERATING IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 39: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
  • TABLE 40: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
  • TABLE 41: KEY PLAYERS OPERATING IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
  • TABLE 42: LIST OF MERGERS & ACQUISITIONS
  • TABLE 43: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 44: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 45: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: GROWTH PROSPECT MAPPING
  • FIGURE 4: MARKET MATURITY ANALYSIS
  • FIGURE 5: MARKET CONCENTRATION ANALYSIS
  • FIGURE 6: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY DEPLOYMENT, IN 2023
  • FIGURE 7: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY ON-PREMISE, 2024-2032 (IN $ MILLION)
  • FIGURE 8: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY WEB-BASED, 2024-2032 (IN $ MILLION)
  • FIGURE 9: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY CLOUD-BASED, 2024-2032 (IN $ MILLION)
  • FIGURE 10: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023
  • FIGURE 11: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY INFECTION PREDICTION & FORECASTING, 2024-2032 (IN $ MILLION)
  • FIGURE 12: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DISEASE & SYNDROMIC SURVEILLANCE, 2024-2032 (IN $ MILLION)
  • FIGURE 13: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE, 2024-2032 (IN $ MILLION)
  • FIGURE 14: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY END USE, IN 2023
  • FIGURE 15: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GOVERNMENT & STATE AGENCIES, 2024-2032 (IN $ MILLION)
  • FIGURE 16: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY RESEARCH LABS, 2024-2032 (IN $ MILLION)
  • FIGURE 17: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2024-2032 (IN $ MILLION)
  • FIGURE 18: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY HEALTHCARE PROVIDERS, 2024-2032 (IN $ MILLION)
  • FIGURE 19: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 20: UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 21: CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 22: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 23: UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 24: GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 25: FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 26: ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 27: SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 28: REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 29: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 30: CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 31: JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 32: INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 34: AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 35: REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 36: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)
  • FIGURE 37: LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)
  • FIGURE 38: MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)